Posted by Michael Wonder on 07 Dec 2024
FDA approves durvalumab for limited-stage small cell lung cancer
4 December 2024 - Today, the FDA approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
Efficacy was evaluated in ADRIATIC, a randomised, double-blind, placebo-controlled trial in 730 patients with limited-stage small cell lung cancer whose disease had not progressed following concurrent platinum-based chemotherapy and radiation therapy.
